Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
niix is a fitness app plugging the gap in the market for women approaching 40. Since its launch in 2018, the company has created a 4+ star rated app with more than 1800 paid subscriptions across 25 countries including the US, Canada, and Australia. It also has an online following of tens of thousands. The global fitness app market is growing fast set to be worth $2 billion by 2023 with a focus on weight loss and body aesthetics for millennial markets. niix sees a huge opportunity in this space to support women who have simply outgrown an approach that want the perfect body and be fit lifelong. With the investment, the company will scale up proven marketing channels to grow community and subscriber bases, making niix the no.1 digital fitness brand for women approaching 40+.
days to go:
Expired
investment:
£153,441
Mindful uses blockchain, artificial intelligence (AI) and video technologies to deliver mental health recovery programmes for 8 to 25-year-olds. With the help of their technology, the therapists work with families and schools to change the way of providing mental health services. The company has a powerful management team experience in business, healthcare and education. Mindful is currently running a pilot project and is signing up schools in the West Midlands. The company is signing partnerships with 6 Multi Academy Trusts with further trust to sign > 50 schools.
days to go:
Expired
investment:
£91,850
ValuedByUs have a mission to disrupt High Street banking by providing a low-cost bank experience. They are planning a low-cost operating model, which would result in higher rates for savers and in lower rates for borrowers.
days to go:
Expired
investment:
£25,830
Recasher is a e-money based loyalty programme offering real cash back instantly. One app replaces hundreds of loyalty cards offering users significant savings on day to day items and providing merchants the information to make personalised promotions.
days to go:
Expired
investment:
£153,200
Abundance is an alternative finance platform that lets people get directly involved in the transition to 'Net Carbon Zero' by enabling them to engage in 'Green Investments'. The company has a base of 6,800 customers who collectively share a desire to create a greener world. Abundance launched its new product 'Community Municipal Investments' (CMI) in July 2020. Its first investment with West Berkshire Council already has over 400 investors. It has also launched other financial products such as 'Innovative Finance' Individual Savings Account (ISA) and a Self-Invested Personal Pension (SIPP). Abundance has already put over £100 million into green energy and green social housing projects. It will use the investment to establish CMIs as the way to fund councils and engage citizens in green activities, cement its position in 'Net Zero' investments, and secure a strategic partner to grow more quickly.
days to go:
Expired
investment:
£702,620
Nova is a Venture Capital (VC) company that endeavours to back brilliant people who want to build notable companies that will change the world. Nova provides funding, guidance, and workforce to startups and helps them become profitable enterprises. The company meets around 2000 potential founders every year and becomes a co-founder of 20+ startups that it finds hold promise. Nova has created over £100 million of shareholder value. It also asserts that the three-year survival rate of its portfolio companies stands at 46% as compared to market norms of around 8-10%. The company will use £1 million of new capital investment to bolster the growth of its operational capacity to enable more successful ventures with amazing founders. It will also use the investment to be listed on a public market within a 3-5 year timeframe.
days to go:
Expired
investment:
£1,013,560
